Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRhythm Technologies, Inc. (NASDAQ: IRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer. As a digital health care company focused on ambulatory cardiac monitoring and data analytics, iRhythm uses its SEC reports to communicate financial performance, risk factors, governance matters, and material corporate events related to its Zio long-term continuous monitoring (LTCM) service and broader operations.
Investors can use this page to review current and historical filings retrieved from the SEC’s EDGAR system, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Recent 8-K filings have covered topics such as quarterly financial results, investor presentations, and amendments to the Executive Change in Control and Severance Policy, which outlines severance payments, COBRA coverage, and equity vesting treatment for senior leaders under specified termination scenarios.
For those analyzing iRhythm’s business in more depth, the company’s periodic reports typically discuss revenue from Zio services, gross margins, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted net loss, and liquidity metrics such as cash, cash equivalents, and marketable securities. These documents also describe how iRhythm accounts for items like stock-based compensation, business transformation costs, and other adjustments that affect non-GAAP results.
Stock Titan enhances access to these filings with AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. Users can quickly identify major changes in financial condition, updates to risk disclosures, and details of insider or executive-related arrangements that appear in forms and exhibits. This combination of real-time filing access and AI-generated insights can support investors, analysts, and other stakeholders who want to understand how iRhythm reports on its digital cardiac monitoring business and corporate governance over time.
iRhythm Technologies, Inc. (NASDAQ: IRTC) – Form 144 filing overview
On the latest Form 144 notice, insider Daniel Wilson has disclosed a proposed sale of 3,000 common shares of iRhythm Technologies. The sale will be executed through Morgan Stanley Smith Barney LLC on or about 23 June 2025. Based on the filing’s stated price, the transaction is valued at approximately $450,000.
iRhythm reports 31,925,267 shares outstanding; the proposed sale therefore equals roughly 0.009 % of the company’s issued shares. The shares being sold were originally acquired via company equity awards: 1,063 performance shares (27 Feb 2023), 970 restricted shares (1 Mar 2023) and 967 performance shares (27 Feb 2024).
The filing also lists insider sales during the previous three months: on 2 May 2025, Wilson sold 333 and 1,667 common shares for total gross proceeds of $250,000. The Form 144 certification states that the seller affirms no knowledge of undisclosed material adverse information at the time of filing.
Because the notice covers a relatively small portion of total shares outstanding and does not introduce new corporate information, the immediate market impact is expected to be limited; nevertheless, investors often track insider activity for signalling purposes.
iRhythm Technologies (NASDAQ: IRTC) has filed a Form 144 notice for a proposed sale of securities by an insider. The filing details planned sales of 936 shares of common stock with an aggregate market value of $140,400, to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ exchange around June 23, 2025.
The securities were originally acquired as Restricted Stock from the issuer on March 1, 2025. The selling party, Chad Patterson, has conducted several previous transactions in the past 3 months totaling:
- 363 shares sold on June 10, 2025 ($54,450)
- 8,510 shares sold on May 2, 2025 ($1,025,897.50)
The total outstanding shares of iRhythm Technologies are reported at 31,925,267. This Form 144 filing indicates the seller's representation that they are not aware of any material adverse non-public information regarding the company's operations.